Chronic Treatment with Multi-Kinase Inhibitors Causes Differential Toxicities on Skeletal and Cardiac Muscles

Chronic Treatment with Multi-Kinase Inhibitors Causes Differential Toxicities on Skeletal and Cardiac Muscles

Despite recent progress, chemotherapy remains the preferred treatment for cancer. We have shown a link between anticancer drugs and the development of cachexia, i.e., body wasting accompanied by muscle loss. The multi-kinase inhibitors (MKIs) regorafenib and sorafenib, used as second-line treatment...

Full description

Bibliographic Details
Main Authors: Joshua R. Huot, Alyson L. Essex, Maya Gutierrez, Rafael Barreto, Meijing Wang, David L. Waning, Lilian I. Plotkin, Andrea Bonetto
Format: Article
Language:English
Published: MDPI AG 2019-04-01
Series:Cancers
Subjects:
chemotherapy
skeletal muscle wasting
cardiac cachexia
sorafenib
regorafenib
Online Access:https://www.mdpi.com/2072-6694/11/4/571

Similar Items

Similar Items